Device Trial Radar · NCT07934407
HBOT for Perianal Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jul 1, 2027
Primary completion
Apr 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- Barts & The London NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background Perianal fistulae are among the most disabling complications of Crohn's disease, causing significant morbidity, impaired quality of life, and substantial healthcare utilisation. Despite advances in biologic and surgical therapies, many patients experience persistent fistula drainage and fail to achieve durable healing. Tissue hypoxia is a key regulator of intestinal inflammation and impaired wound healing in inflammatory bowel disease. Hyperbaric oxygen therapy (HBOT) increases tissue oxygenation, promotes angiogenesis, modulates inflammatory pathways, and may enhance fistula healing. Preliminary studies suggest that HBOT is a safe and effective adjunctive treatment for refractory perianal Crohn's fistulae, with reported clinical response rates of 75-87% and remission rates of 50-60%. However, current evidence is limited by small sample sizes and the absence of prospective studies within UK clinical practice. Aim To evaluate the preliminary efficacy of HBOT in patients with refractory perianal Crohn's fistulae treated in an outpatient setting. Methods This prospective pilot study will recruit ten adults with refractory perianal Crohn's fistulae from the Inflammatory Bowel Disease service at Barts Health NHS Trust. Refractory disease will be defined as persistent fistula drainage or failure to heal despite optimised medical therapy and appropriate surgical management. Participants will undergo HBOT 100% oxygen at 2.4 ATA for approximately 90 minutes per session, 40 sessions over 8 weeks. The primary outcome will be overall clinical response, defined as either clinical remission (complete cessation of fistula drainage) or partial response (clinically meaningful reduction in drainage and symptoms). Secondary outcomes will include treatment adherence, safety, tolerability, patient acceptability, and feasibility of recruitment and study completion. Expected Impact This pilot study will generate preliminary efficacy and feasibility data to inform the design, outcome measures, and sample size calculations of a larger clinical trial evaluating HBOT as a novel treatment strategy for refractory perianal Crohn's disease in the United Kingdom.
Conditions
- Perianal Crohn Disease
Interventions
Hyperbaric Oxygen Therapy (HBOT)Device
Participants with refractory perianal Crohn's disease fistulae will receive hyperbaric oxygen therapy (HBOT) in addition to standard medical care. HBOT consists of 40 treatment sessions delivered over approximately 8 weeks, with participants breathing 100% oxygen at 2.4 atmospheres absolute (ATA) for approximately 90 minutes per session in a multiplace hyperbaric chamber
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response of Perianal Crohn's Disease FistulaeTime frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Whipps Cross University Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.